Association of high mortality with extended-spectrum β-lactamase (ESBL) positive cultures in community acquired infections

J Crit Care. 2018 Apr:44:255-260. doi: 10.1016/j.jcrc.2017.10.036. Epub 2017 Oct 31.

Abstract

Purpose: Infections due to multidrug resistant organisms have become a serious health concern worldwide. The present study was conducted to investigate the spectrum of microbial resistance pattern in the community and their effects on mortality.

Methods: A retrospective review and analysis of prospectively collected data was done of all patients admitted with diagnosis of sepsis in two tertiary care ICU's for a period of two years. Demographics, culture positivity, microbial spectrum, resistance pattern and outcome data were collected.

Results: Out of 5309 patients enrolled; 3822 had suspected clinical infection on admission with 1452 patients growing positive microbial cultures. Among these, 201 bacterial strains were isolated from patients who had community acquired infections. 73% were Gram negative bacilli, commonest being E. coli (63%). 63.4% E. coli and 60.7% Klebsiella isolates were ESBL producers. The mortality in ESBL positive infections was significantly higher as compared to ESBL negative infections (Odds ratio 2.756). Moreover, ESBL positive patients empirically treated with Beta Lactams+Beta Lactamase inhibitors (BL+BLI) had significantly higher mortality as compared to patients treated with carbapenems. More data from multiple centres need to be gathered to formulate appropriate antibiotic policy for critically ill patients admitted from the community.

Keywords: BL+BLI; Community-acquired infections; ESBL; ESBL positive; Mortality.

Publication types

  • Multicenter Study

MeSH terms

  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use*
  • Community-Acquired Infections / drug therapy*
  • Community-Acquired Infections / microbiology
  • Community-Acquired Infections / mortality
  • Drug Administration Schedule
  • Drug Resistance, Multiple, Bacterial*
  • Escherichia coli / drug effects
  • Escherichia coli / enzymology
  • Escherichia coli / isolation & purification
  • Escherichia coli Infections / drug therapy
  • Escherichia coli Infections / microbiology
  • Escherichia coli Infections / mortality
  • Female
  • Hospital Mortality
  • Humans
  • India
  • Intensive Care Units
  • Klebsiella / drug effects
  • Klebsiella / enzymology
  • Klebsiella / isolation & purification
  • Klebsiella Infections / drug therapy
  • Klebsiella Infections / microbiology
  • Klebsiella Infections / mortality
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Prospective Studies
  • Retrospective Studies
  • Sepsis / drug therapy*
  • Sepsis / microbiology
  • Sepsis / mortality
  • beta-Lactamases / metabolism

Substances

  • Anti-Bacterial Agents
  • beta-Lactamases